Hansa licenses enzyme pretreatment for gene therapy

By The Science Advisory Board staff writers

July 2, 2020 -- Hansa Biopharma has entered into an agreement with Sarepta Therapeutics for an exclusive worldwide license to develop and promote imlifidase as a pretreatment for gene therapy treatment of Duchenne muscular dystrophy and limb-girdle muscular dystrophy.

The pretreatment is an enzyme-based antibody enhancement therapy and is intended for patients with preexisting neutralizing antibodies to adeno-associated virus (AAV), the basis of Sarepta's gene therapy products. Sarepta will be responsible for conducting preclinical and clinical studies with imlifidase and also for any subsequent regulatory approvals. Sarepta will promote imlifidase as a pretreatment following successful approval.

Under the agreement, Hansa will receive a $10 million upfront payment and is eligible for development, regulatory, and sales milestone payments. Hansa will also receive royalties on Sarepta's incremental gene therapy sales when imlifidase gene therapy is enabled by pretreatment.

CSL Behring, Seattle Children's to develop gene therapies
CSL Behring, a biotechnology company, and Seattle Children's Research Institute announced that the organizations have entered a strategic alliance to...
Novasep, Lysogene partner for gene therapy
Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector-based...
Avrobio moves forward with gene therapy candidate
Avrobio released preclinical data for AVR-RD-03, lentiviral gene therapy for Pompe disease, at the American Society of Gene and Cell Therapy annual meeting...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter